Source: Fox News
Summary
A recent preclinical study found that the blood pressure drug telmisartan may improve the effectiveness of a cancer treatment called olaparib. The study, conducted by researchers at Dartmouth Health, showed that telmisartan increased the production of type I interferons, which help the immune system recognize and attack cancer cells. The combination of telmisartan and olaparib was found to be more effective in laboratory and animal models than olaparib alone. The study’s lead author, Tyler J. Curiel, MD, said that the findings suggest that telmisartan could improve the effectiveness of certain cancer therapies. However, the study’s limitations include its reliance on laboratory models and lack of human patients.
Our Reading
The recommendation enters another phase.
The study’s findings may seem promising, but it’s essential to note that the research is still in its early stages. The use of laboratory models rather than human patients is a significant limitation. Additionally, the study’s results may not be applicable to all types of cancer. The researchers are currently testing telmisartan’s effect on patients in two clinical trials. As with any new cancer treatment, more research is needed to determine its safety and effectiveness. The familiar cycle of hope and caution continues in the pursuit of cancer treatment breakthroughs.
Author: Evan Null
